Acrux Submits Application for Ellavie to TGA

Australian drugmaker Acrux has submitted a Category 1 application to the Therapeutic Goods Association (TGA) for Ellavie, an estradiol skin spray for the treatment of vasomotor symptoms associated with menopause.

Following approval of the application, Ellavie will be distributed by South African Aspen Pharmacare’s Australian subsidiary. Acrux said it expects Ellavie to be available in Australia in 2009.

The spray will be launched in the U.S. as Evamist by KV Pharmaceutical.